Navigation Links
BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
Date:7/10/2012

NEWPORT NEWS, Va., July 10, 2012 /PRNewswire/ -- According to a new study by Korean researchers at the Ewha Women's Hospital in Seoul, published this year in the Annals of Nuclear Medicine, Molecular Breast Imaging (MBI), also known as BSGI, may be a better choice than MRI for women who have a new cancer diagnosis and dense breast tissue detected by mammography. According to their results, MBI/BSGI and MRI had nearly the same sensitivity for the detection of additional malignant tumors, but MBI/BSGI was much less likely to be positive in benign lesions.

In their work, Dr. Kim and his colleagues evaluated 66 patients who had a new breast cancer diagnosis and a reported mammography breast density of greater than 50% with MBI/BSGI and MRI prior to surgery. Both MBI/BSGI and MRI detected disease not seen by mammography, however, the MBI/BSGI was more accurate than MRI in determining if lesions were benign or malignant. Only 26% of the additional lesions detected by MRI were malignant compared to MBI/BSGI where 76% of the lesions detected were malignant. This is important for the newly diagnosed breast cancer patient since biopsy is required when imaging studies are positive. Therefore, MBI/BSGI could have led to a large decrease in the number of unnecessary biopsies for women in this trial. According to Dr. Kim, "The results of this study suggest that MBI/BSGI could play a crucial role as an adjunctive imaging modality which can be used to evaluate breast cancer patients with dense breasts."

About Dilon Diagnostics

Dilon Diagnostics®, a brand of Dilon Technologies® Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of-view gamma camera, optimized to perform MBI/BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering MBI/BSGI to their patients, such as Cornell University Medical Center, New York and George Washington University Medical Center, Washington, D.C. As part of Dilon's commitment to offering complete solutions, the new declipseSPECT is the first intra-operative handheld 3D image viewing and navigation solution with applications in SLNB breast, I-125 Seed Localization, SLNB Head and Neck etc. For more information on Dilon Technologies® please visit www.molecularbreastimaging.com

Media contact: Pjerin Luli
P: 757-269-4910
E: pluli@dilon.com


'/>"/>
SOURCE Dilon Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The 2012 US Molecular Diagnostics Market
2. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
3. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
4. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
5. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
6. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
7. Hologic Breast Tomosynthesis (3D Mammography) System Places First in KLAS Annual Survey of Mammography Equipment Users
8. Breast Cancer Detection and Treatment Recovers Slowly from Big Losses During Recession
9. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
10. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
11. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... SANTA MONICA, Calif. , Dec. 5, 2016 /PRNewswire/ ... PINK: PRLX), is pleased to announce that its pharmaceutical ... serve Medicare B clients, allowing coverage in all of ... business in. Michael Rashti Pharm ... "This is a very exciting for our business. Medicare ...
(Date:12/5/2016)... Dec. 5, 2016  Pennsylvania Physician General Dr. ... Programs Gary Tennis today filled prescriptions for ... Pharmacy in York to demonstrate ... Dr. Levine as a prescription to acquire naloxone at ... important to remember that any Pennsylvanian can walk up ...
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. ... the Commercialization of Public Research (the Florida ... funding agreement SegAna, LLC, an Orlando ... of Central Florida. The Florida Institute supports new ... early funding gaps for companies spinning out of Florida-based ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive Laboratories™ is one ... glutathione to enhance production of nitric oxide (NO). , NitroGenesis Pro™ is made ... NO twice as effectively and sustains NO blood levels twice as long as ...
(Date:12/5/2016)... ... December 05, 2016 , ... Eating disorders are equal ... Castlewood Treatment Centers has always been to promote the power of recovery, and ... possible. In that spirit, Castlewood has announced two new hires, both Outreach Directors ...
(Date:12/5/2016)... ... December 05, 2016 , ... U.S. Apple Association (USApple) begins the ... the second annual Apples for Education: Buy an Apple, Help a Student ... food for students to take home to their families; solar technology to efficiently process ...
(Date:12/5/2016)... GREENWICH, CT and MALVERN, PA (PRWEB) , ... ... ... Clinical Supplies Management ("CSM"), a Great Point Partners ("GPP") portfolio company, ... Clinical Research – Clinical Supplies ("TCS"). TCS was previously a subsidiary ...
(Date:12/5/2016)... ... 05, 2016 , ... The legislation – S2718A/A2116A ... a licensed physical therapist, to render care for certain patients. In most cases, ... a licensed physical therapist (PT) and throughout the treatment cycle is supported by ...
Breaking Medicine News(10 mins):